Compare Ascendis Pharma A/S (ASND) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

DNA trades at $9.09, down 6.58% on the day, reflecting ongoing investor caution. The technical outlook is bullish based on moving averages, with key support at $9 and resistance at $10. Fundamentally, the company reported a net loss of $312.76M on $170.16M revenue in 2025, with a negative net margin of -201.05%. Recent news highlights include Ginkgo Bioworks' Q1 2026 results and its strategic pivot to autonomous laboratories following the divestiture of its biosecurity business.

The outlook remains challenging due to persistent losses and high cash burn, though the technical setup suggests potential for a near-term bounce. Investment opportunity hinges on successful execution of the new lab strategy driving future profitability. Key risks include continued negative earnings, competitive pressures in biotech, and reliance on the unproven autonomous lab model for growth.